地特胰岛素联合格列美脲治疗2型糖尿病的观察  

Efficacy of Combination of Insulin Detemir and Glimepiride for the Treatment of T2DM Patients

作　　者：马虹[1] 王翠萍[1] 何勇[1] 

机构地区：[1]包头市蒙中医院内分泌科,内蒙古包头014040

出　　处：《中国医药指南》2014年第11期18-19,共2页Guide of China Medicine

摘　　要：目的观察地特胰岛素联合格列美脲治疗2型糖尿病的疗效。方法 60例2型糖尿病患者随机分为两组,A组为地特胰岛素联合格列美脲组,B组为生物合成人胰岛素注射液(NPH)联合格列美脲组。观察两组患者空腹血糖、(FBG)餐后2 h血糖(2hBG)、糖化血红蛋白(HbA1c)、胰岛素用量、低血糖发生率。结果两组治疗后,FBG、2hBG、HbA1c水平均较治疗前明显下降(P<0.05),二者间比较无统计学意义(P>0.05)。A组胰岛素用量、低血糖发生率明显低于B组(P<0.05)。结论地特胰岛素联合格列美脲降糖效果好,低血糖发生率低,安全方便。Objective To investigate the effects of detemir and glimepiride for the treatment of T2DM patients. Methods 60 T2DM patients were divided into the detemir and glimepiride group and （A, n=30） and NPH group（B, n=30）. The observation of the changes in the levels of FBG, 2hBG, HbA1c, the amount of insulin dosage, incidence rate of hypoglycemia. Results After the treatment for 12 weeks, the levels of FBG, 2hBG, HbA1c were decreased signiifcantly from baseline in both groups （P〈0.05）. Compared with group B, A group amount of insulin and, incidence rate of hypoglycemia were all lower （P〈0.05）. Conclusion A good therapeutic effect is achieved in the treatment with detemir and glimepiride for T2DM with a lower incidence of hypoglycemia and has a good safety.

关 键 词：地特胰岛素 格列美脲 糖尿病 2型 疗效 低血糖 TYPE 2 

分 类 号：R587.1[医药卫生—内分泌]